Testing Endostar for brain swelling after radiation in lung cancer that spread to the brain

Official title: Early Prophylactic Versus Late Salvage Recombinant Human Endostatin in Managing Radiosurgery-Induced Brain Injury for NSCLC Brain Metastases

Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.

The trial team last updated this record on October 1, 2026.

The short version

This trial tests a drug called Endostar for brain swelling after a focused radiation treatment.

Read our full plain-language summary

What the trial team says

Primary Purpose:To preliminarily evaluate the efficacy and safety of recombinant human endostatin (Endostar) in the early prophylactic cohort (Cohort A) and late salvage cohort (Cohort B) for radiation-induced brain injury after stereotactic radiosurgery (SRS) in patients with non-small cell lung cancer (NSCLC) brain metastases, with a focus on the improvement rate of peritumoral brain edema.Secondary Purpose:To explore the effects of Endostar treatment on neurological function, quality of life, and survival outcomes in patients with NSCLC brain metastases following SRS; and to evaluate the convenience and compliance of the "72-hour continuous intravenous pump infusion" regimen.

From the trial's own listing on ClinicalTrials.gov.

Key facts

Registry number: NCT07841106
Stage of testing: Phase 2
Conditions studied: Lung Cancer (Non-Small Cell), Radiation, Brain Injury, Brain Edema, Brain Necrosis

Where it is running

No locations are listed for this trial. The trial's own page may have more.

How to use this

Talk to your care team first. They know your history and can tell you whether this trial is worth your time.

Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.

See the full listing on ClinicalTrials.gov

This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.